NCT06465433 2025-12-10Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With TafasitamabIncyte CorporationPhase 2 Recruiting25 enrolled
NCT05943496 2025-11-06Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaOHSU Knight Cancer InstitutePhase 1 Recruiting27 enrolled